Neurotrope has ownership in some of the outstanding warrants do they not? Hence, they could begin to convert them anytime now as the A/S has increased 10 fold
It would be wise to raise before data. Some will say: if data are good, it doesn't matter. Well, what if data are ambiguous? No biotech wants to put itself in that position.
March will be an interesting month, to say the least. With any significant drop, I will add.
News 
Market Data 
Discover 
